Sitagliptin and cardiovascular outcomes in type 2 diabetes - author's reply by Holman, RR, Peterson, ED

Economic evaluation of factorial trials: cost-utility analysis of the AFORRD 2x2x2 factorial trial of atorvastatin, omega-3 fish oil and action-planning by Dakin, HA, Farmer, A, Gray, AM, Holman, RR

Predicting the risk of developing type 2 diabetes in Chinese people who have coronary heart disease and impaired glucose tolerance by Xu, S, Scott, CAB, Coleman, RL, Tuomilehto, J, Holman, RR

Predicting risk for new-onset type 2 diabetes in Chinese people with coronary heart disease and impaired glucose tolerance by Xu, S, Scott, C, Coleman, RL, Tuomilehto, J, Holman, RR

Estimating cardiovascular risk and all-cause mortality in individuals with type 2 diabetes using the UKPDS Outcomes Model by Coleman, RL, Gray, AM, McGuire, DK, Holman, RR

Development and validation of a five-drug class model using routine clinical features to optimise prescribing in type 2 diabetes by Dennis, JM, Young, KG, Cardoso, P, Farmer, A, Holman, RR

Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes - authors' reply by Nazarzadeh, M, Adler, AI, Chalmers, J, Holman, RR, Rahimi, K

Historical HbA1c values may explain the type 2 diabetes legacy effect: UKPDS 88 by Lind, M, Imberg, H, Coleman, RL, Nerman, O, Holman, RR

Health utilities in Chinese patients with coronary heart disease and impaired glucose tolerance (ACE): a longitudinal analysis of a randomized, double-blind, placebo-controlled tri... by Leal, J, Becker, F, Lim, L-L, Holman, RR, Gray, AM

Increased risk of incident heart failure and death is associated with insulin resistance in people with newly diagnosed type 2 diabetes: UKPDS 89 by Wamil, M, Coleman, RL, Adler, AI, McMurray, JJV, Holman, RR

Increased risk of incident heart failure and all-cause mortality in insulin-resistant people with type 2 diabetes in the United Kingdom Prospective Diabetes Study (UKPDS) by Wamil, M, Coleman, RL, Adler, A, McMurray, JJ, Holman, RR

Modelling incremental benefits on complications rates when targeting lower HbA1c levels in people with Type 2 diabetes and cardiovascular disease by Mostafa, SA, Coleman, RL, Agbaje, OF, Gray, AM, Holman, RR, Bethel, MA

Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91) by Adler, AI, Coleman, RL, Leal, J, Whiteley, WN, Clarke, P, Holman, RR

Estimating risk factor time paths among people with Type 2 Diabetes and QALY gains from risk factor management by Gao, N, Dakin, HA, Holman, RR, Lim, L-L, Leal, J, Clarke, P

Using QALYs as an outcome for assessing global prediction accuracy in diabetes simulation models by Dakin, H, Gao, N, Leal, J, Holman, RR, Tran-Duy, A, Clarke, P

Inflammatory proteins associated with Alzheimer’s disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial by Koychev, I, Reid, G, Nguyen, M, Mentz, RJ, Joyce, D, Shah, SH, Holman, RR

Estimating risk factor progression equations for the UKPDS Outcomes Model 2 (UKPDS 90) by Leal, J, Alva, M, Gregory, V, Hayes, A, Mihaylova, B, Gray, AM, Holman, RR, Clarke, P

Can the cardiovascular risk reductions observed with empagliflozin in the EMPA‐REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor... by Coleman, RL, Gray, AM, Broedl, UC, Fitchett, D, George, JT, Woerle, HJ, Zinman, B, Holman, RR

Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: insights from the Acarbose Cardiovascular Evaluation (ACE) trial by Wamil, M, McMurray, JJV, Scott, CAB, Coleman, RL, Sun, Y, Standl, E, Rydén, L, Holman, RR

Lifetime cost-effectiveness simulation of once-weekly exenatide in type 2 diabetes: a cost-utility analysis based on the EXSCEL trial by Becker, F, Dakin, HA, Reed, SD, Li, Y, Leal, J, Gustavson, SM, Wittbrodt, E, Hernandez, AF, Gray, AM, Holman, RR